Bivalent Gadolinium Ions Forming Injectable Hydrogels for Simultaneous In Situ Vaccination Therapy and Imaging of Soft Tissue Sarcoma

Abstract

AbstractDoxorubicin (DOX) is the classic soft tissue sarcomas (STS) first‐line treatment drug, while dose‐dependent myelosuppression and cardiotoxicity limit its application in clinic. This research intends to apply DOX, which is also an inducer of immunogenic cell death as a part for “in situ vaccination” and conjointly uses PD‐1 inhibitors to enhance antitumor efficacy. In order to achieve the sustained vaccination effect and real‐time monitoring of distribution in vivo, the in situ forming and injectable hydrogel platform with the function of visualization is established for local delivery. The hydrogel platform is synthesized by hyaluronic acid‐dopamine coordinated with gadolinium ions (Gd2+). Gd2+ provides the ability of magnetic resonance imaging, meanwhile further cross‐linking the hydrogel network. Experiments show excellent ability of sustained release and imaging tracking for the hydrogel platform. In mouse STS models, the “in situ vaccination” hydrogels show the best effect of inhibiting tumor growth. Further analysis of tumor tissues show that “in situ vaccination” group can increase T cell infiltration, promote M1‐type macrophage polarization and block elevated PD‐1/PD‐L1 pathway caused by DOX. These results are expected to prove the potential for synthesized hydrogels to achieve a universal platform for “in situ vaccination” strategies on STS treatments.